Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 557

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Bourlière, Marc, Gordon, Stuart C., Flamm, Steven L., Cooper, Curtis L., Ramji, Alnoor, Tong, Myron, Ravendhran, Natarajan, Vierling, John M., Tran, Tram T., Pianko, Stephen, Bansal, Meena B., de Lédinghen, Victor, Hyland, Robert H., Stamm, Luisa M., Dvory-Sobol, Hadas, Svarovskaia, Evguenia, Zhang, Jie, Huang, K.C., Subramanian, G. Mani, Brainard, Diana M., McHutchison, John G., Verna, Elizabeth C., Buggisch, Peter, Landis, Charles S., Younes, Ziad H., Curry, Michael P., Strasser, Simone I., Schiff, Eugene R., Reddy, K. Rajender, Manns, Michael P., Kowdley, Kris V., Zeuzem, Stefan·2017·New England Journal of Medicine

Abstract

BACKGROUND: Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options. METHODS: We conducted two phase 3 trials involving patients who had been previously treated with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1 infection who had previously received a regimen containing an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive either the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor voxilaprevir (150 patients) or matching placebo (150 patients) once daily for 12 weeks. Patients who were infected with HCV of other genotypes (114 patients) were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group. In POLARIS-4, patients with HCV genotype 1, 2, or 3 infection who had previously received a DAA regimen but not an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive sofosbuvir-velpatasvir-voxilaprevir (163 patients) or sofosbuvir-velpatasvir (151 patients) for 12 weeks. An additional 19 patients with HCV genotype 4 infection were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group. RESULTS: In the three active-treatment groups, 46% of the patients had compensated cirrhosis. In POLARIS-1, the rate of sustained virologic response was 96% with sofosbuvir-velpatasvir-voxilaprevir, as compared with 0% with placebo. In POLARIS-4, the rate of response was 98% with sofosbuvir-velpatasvir-voxilaprevir and 90% with sofosbuvir-velpatasvir. The most common adverse events were headache, fatigue, diarrhea, and nausea. In the active-treatment groups in both trials, the percentage of patients who discontinued treatment owing to adverse events was 1% or lower. CONCLUSIONS: Sofosbuvir-velpatasvir-voxilaprevir taken for 12 weeks provided high rates of sustained virologic response among patients across HCV genotypes in whom treatment with a DAA regimen had previously failed. (Funded by Gilead Sciences; POLARIS-1 and POLARIS-4 ClinicalTrials.gov numbers, NCT02607735 and NCT02639247 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1613512

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 557

Metadata

Authors
Bourlière, M., Gordon, S. C., Flamm, S. L., Cooper, C. L., Ramji, A., Tong, M., Ravendhran, N., Vierling, J. M., Tran, T. T., Pianko, S., Bansal, M. B., de Lédinghen, V., Hyland, R. H., Stamm, L. M., Dvory-Sobol, H., Svarovskaia, E., Zhang, J., Huang, K. C., Subramanian, G. M., Brainard, D. M., McHutchison, J. G., Verna, E. C., Buggisch, P., Landis, C. S., Younes, Z. H., Curry, M. P., Strasser, S. I., Schiff, E. R., Reddy, K. R., Manns, M. P., Kowdley, K. V., & Zeuzem, S.
Venue
New England Journal of Medicine
Published
2017-06
Volume
376
Issue
22
Pages
2134-2146
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2617500612
Cited by
557
References
9
FWCI
51.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. https://app.cochat.ai/papers/10.1056/nejmoa1613512
The paper
Bourlière, M., Gordon, S. C., Flamm, S. L., Cooper, C. L., Ramji, A., Tong, M., Ravendhran, N., Vierling, J. M., Tran, T. T., Pianko, S., Bansal, M. B., de Lédinghen, V., Hyland, R. H., Stamm, L. M., Dvory-Sobol, H., Svarovskaia, E., Zhang, J., Huang, K. C., Subramanian, G. M., . . . Zeuzem, S. (2017). Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1613512

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.